Group items tagged

With more than half of the UK population experiencing gum problems and many not believing their condition warrants treatment, there is a significant need for an oral care range that promotes good gum health and prevents future issues. Corsodyl is set to launch a new Gum Strength & Protect line, featuring two toothpastes and a daily mouthwash which are clinically proven to protect against gum problems. This range aims to meet the growing consumer demand for oral care solutions that help proactively manage gum health and prevent issues related to poor oral hygiene. The Corsodyl Gum Strength & Protect line is designed to strengthen the gum seal around teeth, offering long-lasting protection. The product is enriched with hyaluronic acid, a key building block for strong gums, and includes IPMP (Isopropyl Methylphenol) and zinc as antibacterial active ingredients.

Choosing the best toothpaste could be a difficult job as there are so many brands in the market, all claiming that they are the best. Here are 7 tips on how to choose the right toothpaste.

According to the study finding, all personal care products contain 0.1% to 0.3% of triclosan. Shockingly, 72.8% of samples of two items of everyday use, tested positive for triclosan.

Pfizer's plan to sell its Haleon stake is not a surprise, the consumer health company's finance chief Tobias Hestler told Reuters on Wednesday (3 May). London-listed Haleon was carved out as an independent company in July and comprises consumer health assets once owned by GSK and Pfizer. Pfizer, which has a 32% stake in the maker of Sensodyne toothpaste and Panadol painkillers, told the Financial Times on Tuesday that it intends to offload that stake in a "slow and methodical" manner within months. Hestler said Pfizer has long been clear about its intention to sell off the stake, suggesting that the reason the potential of the selloff has gained traction is because the selling window opens around the time that Haleon's results are announced. "This will happen every quarter from now until they're sold off…this is just what's expected," he said, adding: "If I get a courtesy call the evening before they do it then that would be nice, but they don't even have to do that." Shares of the world's biggest standalone consumer health business were down more than 3% in early trading.

In a long scripted overhaul of its business, GlaxoSmithKline spun off its consumer health business on Monday (July 18) in the biggest listing in Europe for more than a decade. The new company, Haleon, becomes the world's biggest standalone consumer health business, home to brands including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu. Shares in Haleon started trading at 330 pence on Monday morning, giving the business a market valuation of around £30.5 billion - dashing high hopes for Haleon's much higher market valuation after GSK in January said it had rebuffed a £50 billion offer from Unilever on the basis it was too low. The major strategy shift by GSK chief executive Emma Walmsley to focus on the company's core pharmaceuticals business comes after she faced intense activist shareholder pressure over its delays in producing Covid jabs and treatments.

US drugs giant Pfizer will exit its consumer healthcare joint venture with GlaxoSmithKline after the unit is spun off next month, the British drugmaker said Wednesday (June 1). GSK will list the healthcare division on the London stock market on July 18 as it looks to concentrate on the pharmaceutical business, it said in a statement. The London-listed firm currently owns a majority 68 percent of the unit, with Pfizer holding the remainder. "Pfizer intends to exit its 32-percent ownership interest in Haleon in a disciplined manner, with the objective of maximising value for Pfizer shareholders," GSK said. Covid jab maker Pfizer is seeking to pursue its focus on "innovative medicines and vaccines", it noted. The unit, which will be named Haleon after the demerger, makes products including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu.

Haleon, the consumer healthcare giant behind brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut down its Maidenhead manufacturing site in the UK. This decision will impact 435 employees and comes as part of a broader strategic realignment of the company's global manufacturing operations according to BBC. The Maidenhead facility, which has been in operation for years, manufactures some of Haleon's most popular oral health products, including Sensodyne and Parodontax. However, following a comprehensive review of its manufacturing capabilities, the company has concluded that the site is no longer economically viable. In a statement issued by a spokesperson for Haleon, they stated, "Following a strategic review of our global manufacturing capabilities, we have determined that our Maidenhead site is no longer a viable option for the manufacture of our products."

Acne is a common skin condition that affects lots of people in their teenage. Here is the list of natural ways to get rid of acne. You probably have been in a state where red spot appears just a night before the big event or occasion.